-
US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee
Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretary, his department announced.
-
Rovtidskriftsjägaren om sin ärkefiende: ”Ondskans imperium”
Han myntade begreppet rovtidskrifter och gjorde ett första försök att kartlägga deras utbredning. Nu berättar bibliotekarien Jeffrey Beall om konsekvenserna det fick för honom. Det här är del fyra i Life Science Swedens artikelserie om rovtidskrifter.
-
Several departures at the top at Nykode
Members of both the management and the board are leaving the Norwegian biotech company Nykode.
-
A tiny animal with great importance
From the mythical Ganges River to the less sacred, but considerably cleaner waters in KI's aquariums in Solna. The little zebrafish has made an unconscious career – as an increasingly important model organism in medical research.
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 out of 21 regions in Sweden. It is also used in neighbouring Nordic countries. “Extremely serious,” says the Sectra CEO to Medtech Magazine.
-
Investment CEO: “The Nordics are outstanding in creating successful medtech companies”
Since the beginning of last month, Susanna Francke Rodau has been a partner and the new CEO of Segulah Medical Acceleration, which invests in medical technology. In an interview she tells about which companies the investment company prefers to invest in, which companies she believes in the most in the portfolio and why she accepted the new position.
-
Grönt ljus för Kennedy sänker läkemedelsbolag
Flera läkemedelsbolag backar på börsen efter att senatskommittén godkänt Robert F. Kennedy Jr som kandidat till landets hälsominister.
-
Life science trends 2025 – Neurology
New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-brain barrier are being developed. In addition, a new type of drug for MS is making its debut. This part of trend insights on life science 2025 is about neurology.